Treatment goals for psoriasis: Should PASI 90 become the standard of care?
Authors:
- 1 April 2015
- journal article
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 106 (3) , 155-157
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Novel systemic drugs under investigation for the treatment of psoriasisJournal of the American Academy of Dermatology, 2012
- Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trialsBritish Journal of Dermatology, 2011
- Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)British Journal of Dermatology, 2011
- Definition of treatment goals for moderate to severe psoriasis: a European consensusArchives of Dermatological Research, 2010
- Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)British Journal of Dermatology, 2007
- Psoriasis: epidemiologyClinics in Dermatology, 2007
- Psoriasis assessment tools in clinical trialsAnnals of the Rheumatic Diseases, 2005
- A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisJournal of the American Academy of Dermatology, 2004
- Psoriasis causes as much disability as other major medical diseasesJournal of the American Academy of Dermatology, 1999
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978